Gilead Sciences, Inc. is a global biopharmaceutical company focused on discovering, developing, and manufacturing antiviral and oncology therapies. Founded in 1987 and headquartered in Foster City, California, the company’s portfolio spans small-molecule drugs and biologics addressing HIV, viral hepatitis B and C, COVID‑19, and cancers. Gilead operates an international R&D and production network, carrying medicines from early discovery through process development and commercial supply.
Notable products include HIV regimens such as Biktarvy and Descovy; antiviral treatments for hepatitis C (e.g., Epclusa, Harvoni) and hepatitis B (e.g., Vemlidy); and the antiviral Veklury (remdesivir) for COVID‑19. In oncology, Gilead markets Trodelvy and, through its Kite subsidiary, autologous cell therapies including Yescarta and Tecartus for certain hematologic malignancies. The company’s activities are closely tied to chemical and bioprocess innovation, including active pharmaceutical ingredient (API) synthesis, formulation, and scale‑up to support global access and supply. Gilead is listed on the NASDAQ under the ticker GILD.
Phase 3 ISLEND-1/2 show once-weekly oral ISL/LEN noninferior to daily regimens at Week 48 with low discontinuations and similar safety profiles.
Late‑breakers include Week 48 results for once‑weekly islatravir+lenacapavir and Week 24 data for islatravir+ulonivirine; once‑monthly PrEP trials are enrolling.
Once‑weekly oral islatravir 2 mg/lenacapavir 300 mg met Week 48 primary endpoint, non‑inferior to Biktarvy and daily standard‑of‑care; safety profile comparable across arms.
eDMC recommended stopping the Phase 3 trial after final PFS and interim OS reviews: PFS trend non‑significant, OS unlikely to be significant; safety profile consistent; ~620 patients enrolled.
Once-daily, tenofovir-free two-drug regimen approved for virologically suppressed adults; Phase 3 non-inferior to BIC/FTC/TAF. Contraindicated with strong CYP3A inducers or 3TC/FTC; skin reactions.
DOR/ISL shows non-inferiority to BIC/FTC/TAF in HIV-1 treatment-naïve adults, meeting efficacy and safety goals. Detailed findings to be presented at a future scientific congress.
Phase 3 trials show minimal weight, body composition, and lipid changes with the DOR/ISL regimen in HIV-1 patients, maintaining viral suppression without resistance.
